Document is current
Any future updates will be listed below
-
Authors
Obermayer, Alyssa N.
Chang, Darwin
Nobles, Gabrielle
Teng, Mingxiang
Tan, Aik-Choon
Wang, Xuefeng
Chen, Y. Ann
Eschrich, Steven
Rodriguez, Paulo C.
Grass, G. Daniel
Meshinchi, Soheil
Tarhini, Ahmad
Chen, Dung-tsa
Shaw, Timothy I.
-
Funding
Funding for this research was provided by:
NIH (P30-CA076292, P30-CA076292, P30-CA076292, P30-CA076292, P30-CA076292, P30-CA076292, P30-CA076292)
American Cancer Society (IRG-21-145-25)
Team Science Award from the Moffitt Cancer Center Quantitative Science Program
Moffitt Cancer Center Department of Biostatistics and Bioinformatics Pilot Award
Florida Department of Health Live Like Bella Pediatric Research Initiative (23L10)
- License Information
-
More Information
Article History
Received: 28 December 2022
Accepted: 19 June 2023
First Online: 28 June 2023
Declarations
:
: Not applicable.
: Not applicable.
: TIS, AO, and DTC report a provisional patent application for the PATH-SURVEYOR software. SAE reports intellectual property (RSI) and stock in Cvergenx. AT reports grants from Bristol Myers Squib, grants from Genentech-Roche, grants from Regeneron, grants from Sanofi-Genzyme, grants from Nektar, grants from Clinigen, grants from Merck, grants from Acrotech, grants from Pfizer, grants from Checkmate, grants from OncoSec, personal fees from Bristol Myers Squibb, personal fees from Merck, personal fees from Easai, personal fees from Instil Bio, personal fees from Clinigin, personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Novartis, personal fees from Partner Therapeutics, personal fees from Genentech/Roche, personal fees from BioNTech, outside the submitted work. DC, GN, MT, ACT, GDG, XW, PR, and SM declare no other conflict of interest.
